What is WAVE Life Sciences Return-on-Tangible-Equity?
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. WAVE Life Sciences's annualized net income for the quarter that ended in Mar. 2025 was $-187.5 Mil. WAVE Life Sciences's average shareholder tangible equity for the quarter that ended in Mar. 2025 was $190.7 Mil. Therefore, WAVE Life Sciences's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2025 was -98.35%.
The historical rank and industry rank for WAVE Life Sciences's Return-on-Tangible-Equity or its related term are showing as below:
WVE'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -282.52 Med: -107.8 Max: -24.69
Current: -103.08
During the past 12 years, WAVE Life Sciences's highest Return-on-Tangible-Equity was -24.69%. The lowest was -282.52%. And the median was -107.80%.
WVE's Return-on-Tangible-Equity is ranked worse than 72.83% of 1255
companies
in the Biotechnology industry
Industry Median: -43.28
vs WVE: -103.08
WAVE Life Sciences Return-on-Tangible-Equity Historical Data
The historical data trend for WAVE Life Sciences's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
WAVE Life Sciences Return-on-Tangible-Equity Chart
Competitive Comparison of WAVE Life Sciences's Return-on-Tangible-Equity
For the Biotechnology subindustry, WAVE Life Sciences's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WAVE Life Sciences's Return-on-Tangible-Equity Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, WAVE Life Sciences's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where WAVE Life Sciences's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
WAVE Life Sciences (NAS:WVE) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
WAVE Life Sciences Return-on-Tangible-Equity Related Terms
Thank you for viewing the detailed overview of WAVE Life Sciences's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
WVE has been successfully added to your 